CellaVision AB
STO:CEVI
CellaVision AB
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Revenue: Net sales were SEK 176 million, down 1.7%, but organic growth was 2.6% due to FX headwinds.
Margins: Gross margin improved by 1 percentage point to 69%, helped by price increases and product mix.
EBITDA: EBITDA rose to SEK 50 million, a small increase from last year, with margin up to 28%.
Cash Flow: Operating cash flow was SEK 29.6 million, impacted by higher accounts receivable after a surge in late Q3 orders.
Regional Performance: Americas and EMEA saw modest organic growth; APAC remained soft but saw strong reagent momentum.
Strategic Progress: Key milestones include completion of bone marrow CE mark submission and rollout of a major software upgrade.
Guidance & Outlook: Management remains confident in ongoing R&D investment and expects the bone marrow CE mark in early 2026, with continued growth focus.
China & APAC: Local manufacturing in China allows participation in tenders but the market is very competitive and sales may remain lumpy.
